Cynosure develops and markets aesthetic treatment systems that enable plastic surgeons, dermatologists and other medical practitioners to perform non-invasive and minimally invasive procedures to remove hair, treat vascular and benign pigmented lesions, remove multi-colored tattoos, revitalize the skin, liquefy and remove unwanted fat through laser lipolysis, reduce cellulite, clear nails infected by toe fungus and ablate sweat glands. Cynosure's product portfolio is composed of a broad range of energy sources including Alexandrite, diode, Nd: YAG, picosecond, pulse dye, and Q-switched lasers and intense pulsed light. Cynosure sells its products globally under the Cynosure, Palomar and ConBio brand names through a direct sales force in the United States, Canada, Mexico, France, Germany, Spain, the United Kingdom, Australia, China, Japan and Korea, and through international distributors in approximately 120 other countries.

CYNO (Common Stock)
ExchangeNASDAQ GS (US Dollar)
Price$24.50
Change (%) Stock is Down 0.17 (0.69%)
Volume225,000
Data as of 04/16/14 4:00 p.m. ET
Minimum 20 minute delay
Refresh quote

News Releases

April 02, 2014
Cynosure Announces 35 Clinical Research Presentations at 34th ASLMS Annual Conference
February 12, 2014
Cynosure Reports Record Fourth Quarter Revenue of $74.5 million, up 75% Year-over-Year
February 06, 2014
Cynosure to Participate in Leerink Swann Global Healthcare Conference 2014

Upcoming Events

There are currently no events scheduled.
Quotes delayed at least 15 minutes. Market data provided by Interactive Data.

Terms & Conditions. Powered and implemented by Interactive Data Managed Solutions.